

# Subhasree Nag

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/925136/publications.pdf>

Version: 2024-02-01

21  
papers

1,622  
citations

567144

15  
h-index

713332

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposure to an Environmental Mixture of Polycyclic Aromatic Hydrocarbons Induces Hepatic Cytochrome P450 Enzymes in Mice. <i>Chemical Research in Toxicology</i> , 2021, 34, 2145-2156.	1.7	10
2	In vitro metabolism of benzo[a]pyrene-7,8-dihydrodiol and dibenzo[def,p]chrysene-11,12 diol in rodent and human hepatic microsomes. <i>Toxicology Letters</i> , 2017, 269, 23-32.	0.4	17
3	Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. <i>Methods in Molecular Biology</i> , 2016, 1406, 271-287.	0.4	3
4	Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. <i>Biomedical Chromatography</i> , 2015, 29, 654-663.	0.8	12
5	Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. <i>Medicinal Research Reviews</i> , 2015, 35, 1220-1267.	5.0	93
6	Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. <i>Chinese Journal of Natural Medicines</i> , 2015, 13, 554-560.	0.7	2
7	Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. <i>Medicinal Research Reviews</i> , 2015, 35, 225-285.	5.0	165
8	Oral nano-delivery of anticancer ginsenoside 25-OCH <sub>3</sub> -PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, <i>in vitro</i> and <i>in vivo</i> anti-prostate cancer activity, and mechanisms of action. <i>Oncotarget</i> , 2015, 6, 21379-21394.	0.8	57
9	Targeting the NF- $\kappa$ B Signaling Pathways for Breast Cancer Prevention and Therapy. <i>Current Medicinal Chemistry</i> , 2014, 22, 264-289.	1.2	178
10	The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. <i>Nature Communications</i> , 2014, 5, 5086.	5.8	70
11	A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 969, 235-240.	1.2	6
12	NFAT as cancer target: Mission possible?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 297-311.	3.3	90
13	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2014, 5, 11604-11619.	0.8	46
14	Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?. <i>Current Medicinal Chemistry</i> , 2014, 21, 553-574.	1.2	110
15	Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from <i>Inula linearifolia</i> Turcz.. <i>European Journal of Medicinal Chemistry</i> , 2013, 68, 473-481.	2.6	41
16	miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents. <i>Current Cancer Drug Targets</i> , 2013, 13, 519-541.	0.8	33
17	The MDM2-p53 pathway revisited. <i>Journal of Biomedical Research</i> , 2013, 27, 254.	0.7	279
18	Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents. <i>Current Cancer Drug Targets</i> , 2013, 13, 596-609.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. <i>Current Medicinal Chemistry</i> , 2012, 19, 5705-5725.	1.2	56
20	Natural Product Ginsenoside 25-OCH <sub>3</sub> -PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2. <i>PLoS ONE</i> , 2012, 7, e41586.	1.1	73
21	Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. <i>Frontiers in Pharmacology</i> , 2012, 3, 25.	1.6	272